Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 3
2017 2
2018 1
2019 1
2020 1
2021 7
2022 3
2023 3
2024 10
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease prevention.
Holtzman NG, Curtis LM, Salit RB, Shaffer BC, Pirsl F, Ostojic A, Steinberg SM, Schulz E, Wilder JS, Hughes TE, Rose J, Memon S, Korngold R, Gea-Banacloche JC, Fowler DH, Hakim FT, Gress RE, Bishop MR, Pavletic SZ. Holtzman NG, et al. Among authors: pirsl f. Blood Adv. 2024 Aug 27;8(16):4294-4310. doi: 10.1182/bloodadvances.2023010973. Blood Adv. 2024. PMID: 38669315 Free PMC article. Clinical Trial.
Long-term follow-up after lymphodepleting autologous haematopoietic cell transplantation for treatment-resistant systemic lupus erythematosus.
Goklemez S, Hasni S, Hakim FT, Muraro PA, Pirsl F, Rose J, Memon S, Fowler DF, Steinberg SM, Baker EH, Panch SR, Gress R, Illei GG, Lipsky PE, Pavletic SZ. Goklemez S, et al. Among authors: pirsl f. Rheumatology (Oxford). 2022 Aug 3;61(8):3317-3328. doi: 10.1093/rheumatology/keab877. Rheumatology (Oxford). 2022. PMID: 34875023 Free PMC article.
Subsequent Cancers in Patients Affected with Moderate or Severe Chronic Graft-versus-Host Disease.
Schaar DA, Pirsl F, Holtzman N, Steinberg SM, Nashed J, Ruben C, Cowen EW, Mays JW, Mitchell S, Ostojic A, Munshi PN, Joe GO, Comis LE, Morton L, Pavletic SZ. Schaar DA, et al. Among authors: pirsl f. Transplant Cell Ther. 2021 Nov;27(11):937.e1-937.e7. doi: 10.1016/j.jtct.2021.08.001. Epub 2021 Aug 8. Transplant Cell Ther. 2021. PMID: 34380090 Free PMC article.
Predictors of hematologic malignancy relapse in patients with advanced chronic graft-versus-host disease.
Ruben CL, Pirsl F, Steinberg SM, Holtzman NG, Parsons-Wandell L, Baruffaldi J, Curtis LM, Mitchell SA, Kerep AZ, Cowen EW, Berger A, Joe GO, Datiles MB 3rd, Mays JW, Pavletic SZ. Ruben CL, et al. Among authors: pirsl f. Bone Marrow Transplant. 2021 Jul;56(7):1584-1592. doi: 10.1038/s41409-021-01211-2. Epub 2021 Feb 1. Bone Marrow Transplant. 2021. PMID: 33526918 Free PMC article.
Determinants and Clinical Significance of Musculoskeletal Symptoms in Patients With Chronic Graft-Versus-Host Disease.
Zelic Kerep A, Pirsl F, Steinberg S, Mitchell S, Curtis L, Holtzman N, Goklemez S, Bilic E, Cowen E, Pichard D, Joe G, Comis L, Im A, Berger A, Parsons-Wandell L, Pulanic D, Baird K, Gress R, Pavletic S. Zelic Kerep A, et al. Among authors: pirsl f. Hemasphere. 2022 May 31;6(6):e730. doi: 10.1097/HS9.0000000000000730. eCollection 2022 Jun. Hemasphere. 2022. PMID: 35747850 Free PMC article.
Clinical characterization and cytokine profile of fatigue in hematologic malignancy patients with chronic graft-versus-host disease.
Goklemez S, Saligan LN, Pirsl F, Holtzman NG, Ostojic A, Steinberg SM, Hakim FT, Rose JJ, Kang Z, Yu Y, Cao L, Mitchell SA, Im A, Pavletic SZ. Goklemez S, et al. Among authors: pirsl f. Bone Marrow Transplant. 2021 Dec;56(12):2934-2939. doi: 10.1038/s41409-021-01419-2. Epub 2021 Aug 25. Bone Marrow Transplant. 2021. PMID: 34433916 Free PMC article.
29 results